Top 10 Rotigotine (Neupro) Generic Manufacturers in India
The generic pharmaceutical market in India is experiencing significant growth, driven by increasing healthcare costs, a rising prevalence of chronic diseases, and a growing demand for affordable medication. According to a report by the Indian Brand Equity Foundation (IBEF), the Indian pharmaceutical market is expected to reach USD 130 billion by 2030, expanding at a CAGR of 12-15%. Rotigotine, marketed under the brand name Neupro, is a critical medication used in the treatment of Parkinson’s disease and Restless Leg Syndrome (RLS). With the increasing global demand for Rotigotine generics, several Indian manufacturers are stepping up to meet market needs.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical is one of India’s largest pharmaceutical companies, with a market share of approximately 8.7% in the Indian pharmaceutical sector. The company produces a variety of generics, including Rotigotine patches. In FY 2022-23, Sun Pharma reported revenues of USD 4.5 billion, with a strong export performance contributing to 50% of its sales.
2. Zydus Cadila
Zydus Cadila, a leading player in the Indian pharmaceutical industry, holds a substantial share in the generics market. The company launched its Rotigotine patch in 2018 and has since captured a significant portion of the market. Zydus Cadila reported a revenue of USD 2.3 billion in FY 2022-23, with a focus on expanding its export portfolio.
3. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is another prominent name in the Indian pharmaceutical sector, providing a range of generic drugs, including Rotigotine. The firm has a robust pipeline and reported a revenue of USD 2.6 billion in FY 2022-23, with exports accounting for over 50% of its total revenue, reflecting its strong international presence.
4. Aurobindo Pharma
Aurobindo Pharma has made significant strides in the generic pharmaceutical market and has recently ventured into the production of Rotigotine patches. The company generated revenues of approximately USD 2.1 billion in FY 2022-23, with exports contributing significantly to its overall performance, especially in regulated markets.
5. Lupin Pharmaceuticals
Lupin Pharmaceuticals is known for its strong portfolio in generic drugs, including Rotigotine formulations. The company reported a revenue of USD 2.2 billion in FY 2022-23, with a consistent focus on expanding its international footprint, particularly in the U.S. and Europe.
6. Mylan Laboratories (now part of Viatris)
Mylan, now part of Viatris, is a global leader in generics and biosimilars. The company offers Rotigotine patches and has a significant market presence in India. Mylan reported a revenue of approximately USD 11.6 billion globally in FY 2022, with a substantial portion derived from its Indian operations.
7. Intas Pharmaceuticals
Intas Pharmaceuticals has grown rapidly in the generics market, including the production of Rotigotine. The company recorded revenues of USD 1.5 billion in FY 2022-23, with significant exports contributing to its growth trajectory, particularly in Europe and the U.S.
8. Torrent Pharmaceuticals
Torrent Pharmaceuticals is well-regarded for its quality generics, including Rotigotine. The company reported revenues of USD 1.3 billion in FY 2022-23, with a focus on both domestic and international markets, enhancing its position in the global pharmaceutical landscape.
9. Alkem Laboratories
Alkem Laboratories has established itself as a key player in the Indian generics market, including Rotigotine formulations. The company reported revenues of USD 1.2 billion in FY 2022-23 and is actively expanding its export operations, particularly in the U.S.
10. Emcure Pharmaceuticals
Emcure Pharmaceuticals offers a range of generic medications, including Rotigotine. The company generated revenues of USD 1 billion in FY 2022-23, with exports contributing significantly to its growth, especially in emerging markets.
Insights
The Indian pharmaceutical industry is witnessing a transformative phase, with the generics market projected to continue expanding. The demand for Rotigotine generics is expected to rise, driven by the increasing prevalence of Parkinson’s disease and RLS. According to market research, the global Rotigotine market is expected to grow at a CAGR of 4.5% from 2023 to 2030, with India playing a crucial role as a manufacturing hub. As more companies invest in research and development, the production capabilities of Rotigotine generics in India are set to increase, supporting both domestic and international markets.
Related Analysis: View Previous Industry Report
